Ianalumab

Ianalumab
Monoclonal antibody
Type	?
Source	Human
Target	BAFF receptor
Clinical data
Other names	VAY736
ATC code	none;
Identifiers
CAS Number	1929549-92-7;
UNII	ZN2GQ3II96;
KEGG	D12151;

Ianalumab (INN;^[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.^[2]^[3]^[4]

This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.^[5]^[6] In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated.^[7]

References

^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
^ "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG.
^ van den Hoogen LL, van Laar JM (February 2020). "Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome". Best Practice & Research. Clinical Rheumatology. 34 (1): 101485. doi:10.1016/j.berh.2020.101485. PMID 32067925.
^ Narain S, Berman N, Furie R (November 2020). "Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis". Current Opinion in Rheumatology. 32 (6): 609–616. doi:10.1097/BOR.0000000000000754. PMID 33002950. S2CID 222150641.
^ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
^ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
^ "Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab". Pharmaceutical Technology. 30 June 2023.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[WHOList117-1] World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).

[2] "Ianalumab - MorphoSys/Novartis". AdisInsight. Springer Nature Switzerland AG.

[pmid32067925-3] van den Hoogen LL, van Laar JM (February 2020). "Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome". Best Practice & Research. Clinical Rheumatology. 34 (1): 101485. doi:10.1016/j.berh.2020.101485. PMID 32067925.

[pmid33002950-4] Narain S, Berman N, Furie R (November 2020). "Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis". Current Opinion in Rheumatology. 32 (6): 609–616. doi:10.1097/BOR.0000000000000754. PMID 33002950. S2CID 222150641.

[5] Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov

[6] Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov

[7] "Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab". Pharmaceutical Technology. 30 June 2023.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Ianalumab

References

Navigation menu

Search